The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant
{{output}}
Activating mutations in FLT3 in acute myeloid leukemia (AML) portend a poor prognosis, and targeting FLT3 with a tyrosine kinase inhibitor has been an area of intense research recently. Most FLT3 mutated AML patients undergo hematopoietic stem cell transplanta... ...
